Central nervous system depression

Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote

Retrieved on: 
Thursday, January 12, 2023

Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote.

Key Points: 
  • Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote.
  • Nerve agents kill brain cells leading to respiratory failure, seizures, and death within minutes of exposure.
  • Previous work in humans completed by Odyssey has shown that intranasal administration of spray-dried powders leads to low plasma concentrations compared to an intravenous route.
  • Oximes are an antidote for organophosphate nerve agents however the current application is through a skin auto-injector.

A&W Canada Partners with Christine Sinclair for the 13th Annual Burgers to Beat MS Campaign to Help Take On Multiple Sclerosis

Retrieved on: 
Wednesday, July 28, 2021

Together, we can make a difference for people, like my mom, who live with MS and whoneed support now!"

Key Points: 
  • Together, we can make a difference for people, like my mom, who live with MS and whoneed support now!"
  • This will be the 13th anniversary, and we want to continue the momentum of raising awareness and important funds for the MS Society."
  • A&W will be donating $2 from every Teen Burger sold on Burgers to Beat MS Day on Thursday, August 19th, to the MS Society.
  • Editor's Note:Your local A&W restaurant, MS Society of Canada chapter and/or other Burgers to Beat MS partners may send you additional details about the campaign.

Sandoz Inc. launches authorized generic version of buprenorphine and naloxone sublingual film

Retrieved on: 
Tuesday, February 19, 2019

Sandoz buprenorphine and naloxone sublingual film (2mg/0.5mg, 4mg/1mg, 8mg/2mg and 12mg/3mg) is indicated for the treatment of opioid dependence.

Key Points: 
  • Sandoz buprenorphine and naloxone sublingual film (2mg/0.5mg, 4mg/1mg, 8mg/2mg and 12mg/3mg) is indicated for the treatment of opioid dependence.
  • Buprenorphine and naloxone sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support.
  • Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with buprenorphine and naloxone sublingual film.
  • Unintentional Pediatric Exposure: Store buprenorphine and naloxone sublingual film safely out of the sight and reach of children.

Perrigo Confirms Patent Challenge For Generic Version Of NarcanĀ®

Retrieved on: 
Friday, October 26, 2018

Narcan (naloxone HCl) Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression.

Key Points: 
  • Narcan (naloxone HCl) Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression.
  • Annual market sales for the 12 months ending August 2018 were $95 million as measured by IQVIA.
  • Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providingQuality Affordable Healthcare Products.
  • Perrigo is the world's largest manufacturer of over-the-counter ("OTC") healthcare products and supplier of infant formulas for the store brand market.